King-Jones Heidy: insider trades.
King-Jones Heidy reported 7 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($2.5M), across 1 company.
- Transactions
- 7
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 1
- Name as filed
- King-Jones Heidy
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Officer · See Remarks | 7 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-02 | Spyre Therapeutics, Inc. | S | 400 | $90 | 2,845 | Form 4 |
| 2026-09-02 | Spyre Therapeutics, Inc. | M | 400 | $14.5 | 3,245 | Form 4 |
| 2026-09-01 | Spyre Therapeutics, Inc. | M | 27,999 | $14.5 | 30,844 | Form 4 |
| 2026-09-01 | Spyre Therapeutics, Inc. | S | 4,845 | $86.4 | 25,999 | Form 4 |
| 2026-09-01 | Spyre Therapeutics, Inc. | S | 16,548 | $87.2 | 9,451 | Form 4 |
| 2026-09-01 | Spyre Therapeutics, Inc. | S | 6,206 | $88.17 | 3,245 | Form 4 |
| 2026-09-01 | Spyre Therapeutics, Inc. | S | 400 | $89.38 | 2,845 | Form 4 |
Questions
What stock did King-Jones Heidy buy or sell?
King-Jones Heidy reported 7 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($2.5M), across 1 company.
Is King-Jones Heidy the same person as other filers with this name?
This page covers SEC CIK 1794898 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/king-jones-heidy-1794898.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.